The 2026 GLP-1 Pivot: Securing High-Value, Verified Retainers
February 26, 2026 by Mohr Marketing

The Compliance Shield: Why Diagnostic Proof is the New Gold Standard

To qualify for a claim in the 2026 Ozempic (Semaglutide) MDL, the court now requires specific medical evidence to distinguish drug-induced injuries from pre-existing conditions.

Use this checklist to determine if a potential claimant meets the February 2026 court standards for Gastroparesis or NAION.

Section 1: Gastroparesis (Stomach Paralysis) Checklist

Per Judge Marston’s 2025/2026 rulings, clinical observation of symptoms is no longer sufficient.

  • [ ] Confirmed Usage: Proof of brand-name Ozempic, Wegovy, or Rybelsus (prescriptions or pharmacy records).
  • [ ] The “Gold Standard” Test: Do you have results from a Gastric Emptying Scintigraphy (GES)?
    • Note: This is the 4-hour nuclear medicine test where you eat a meal (usually eggs) tagged with a tracer.
  • [ ] Alternative Valid Tests: If no GES, do you have results from a Wireless Motility Capsule (SmartPill) or a 13C-Spirulina Breath Test?
  • [ ] Severity Marker: Was the claimant hospitalized or seen in the Emergency Room for persistent vomiting or malnutrition?
  • [ ] Temporal Link: Did the diagnosis occur while actively taking the drug or within 30 days of the last dose?
  • [ ] Exclusions: Ensure the symptoms are not caused by an active bowel obstruction (Ileus) or recent abdominal surgery.

Section 2: NAION (Vision Loss) Checklist

Claims for “Eye Strokes” are handled under the newly formed MDL 3163.

  • [ ] Specialist Diagnosis: Was the NAION diagnosed specifically by an Ophthalmologist or Neuro-Ophthalmologist?
  • [ ] Symptom Documentation: Do medical records note sudden, painless vision loss (often upon waking)?
  • [ ] Objective Findings: Does the record confirm Optic Disc Edema (swelling) or a “pale” optic nerve?
  • [ ] Visual Field Test: Is there a “Humphrey Visual Field” report showing a loss of peripheral or central vision?
  • [ ] Exclusion of Mimics: Have other causes like Giant Cell Arteritis or Optic Neuritis been ruled out by the physician?

Section 3: Legal Quality Indicators (Mohr Marketing Standards)

  • [ ] 1-to-1 Consent: Does the claimant have a TrustedForm or Jornaya certificate proving they explicitly chose your firm?
  • [ ] Identity Verified: Has the claimant passed a banking-grade ID check (e.g., IDology) to prevent bot fraud?
  • [ ] Scammer Scrub™: Has the claimant’s phone/email been scrubbed against the National DNC list and known “serial litigator” databases?

Contact Mohr Marketing today to secure your exclusive, signed GLP-1 retainers and build a cleaner, more valuable docket.

Contact Mohr Marketing today to discuss our GLP-1 Availability.

Ready to fill your docket with valid cases?

Partner with Mohr Marketing to secure high-quality, compliant plaintiffs.

Contact Mohr Marketing to deploy the Compliance Shield today.

Click Here Get a Custom Quote

Let’s discuss your specific needs and how our Compliance Program, AI Lead Generation Technology, digital marketing, and mass tort cases can help you achieve your growth goals.

www.mohrmktg.com 

Mohr Marketing Team

Summary
The 2026 GLP-1 Pivot: Securing High-Value, Verified Retainers
Article Name
The 2026 GLP-1 Pivot: Securing High-Value, Verified Retainers
Description
Secure exclusive, signed GLP-1 retainers. Use Mohr Marketing’s AI WebTracker® and Compliance Shield to build a verified, high-value docket for MDL 3094 & 3163.
Author
Publisher Name
Mohr Marketing, LLC
Publisher Logo
Spread the love
Secret Link